Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Harvard Business School
Baxter
McKinsey
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Chidamide

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Chidamide?

Chidamide is an investigational drug.

There have been 54 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Sichuan University, and Sun Yat-sen University.

There are three US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for Chidamide
TitleSponsorPhase
Biomarker Guided Treatment in DLBCLRuijin HospitalPhase 2
A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaSun Yat-sen UniversityPhase 2
Chidamide and R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaSun Yat-sen UniversityPhase 2

See all Chidamide clinical trials

Clinical Trial Summary for Chidamide

Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide

See all Chidamide clinical trials

US Patents for Chidamide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Chidamide   Start Trial Histone deacetylase inhibitors Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN)   Start Trial
Chidamide   Start Trial Crystal form of chidamide, preparation method and use thereof SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN)   Start Trial
Chidamide   Start Trial Agents for killing HIV-1-infected cells and application thereof KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Chidamide

Drugname Country Document Number Estimated Expiration Related US Patent
Chidamide Australia 2008309269 1989-12-31   Start Trial
Chidamide Canada 2702536 1989-12-31   Start Trial
Chidamide European Patent Office 2205563 1989-12-31   Start Trial
Chidamide Japan 2011501746 1989-12-31   Start Trial
Chidamide Japan 2014144947 1989-12-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Express Scripts
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.